ABT Jan 2026 140.000 call
| Previous Close | 1.9500 |
| Open | 1.7600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 140.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 1.7600 - 1.9500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.22k |
PR NewswireCadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions.
- Insider Monkey
The Most Profitable Biotechnology Company in the World
In this article, we will be taking a look at the most profitable biotechnology company in the world. If you want to learn about more, head straight to the 15 Most Profitable Biotechnology Companies in the World. Global Biotechnology Market Forecast: Strong Growth Driven by Healthcare and Food & Agriculture Innovations The global biotechnology market was valued […]
ZacksAbbott (ABT) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Abbott (ABT) settling at $101.74, representing a +1% change from its previous close.
